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Nomograms for predicting survival of patients with newly
diagnosed glioblastoma: Prognostic factor analysis of EORTC
and NCIC trial 26981-22981/CE.3
Abstract
BACKGROUND: A randomised trial published by the European Organisation for Research and
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials
Group (trial 26981-22981/CE.3) showed that addition of temozolomide to radiotherapy in the treatment
of patients with newly diagnosed glioblastoma significantly improved survival. We aimed to undertake
an exploratory subanalysis of the EORTC and NCIC data to confirm or identify new prognostic factors
for survival in adult patients with glioblastoma, derive nomograms that predict an individual patient's
prognosis, and suggest stratification factors for future trials. METHODS: Data from 573 patients with
newly diagnosed glioblastoma who were randomly assigned to radiotherapy alone or to the same
radiotherapy plus temozolomide in the EORTC and NCIC trial were included in this subanalysis.
Survival modelling was done in three patient populations: intention-to-treat population of all randomised
patients (population 1); patients assigned temozolomide and radiotherapy (population 2, n=287); and
patients assigned temozolomide and radiotherapy who had assessment of MGMT promoter methylation
status and who had undergone tumour resection (population 3, n=103). Cox proportional hazards models
were fitted with and without O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation
status. Nomograms were developed to predict an individual patient's median and 2-year survival
probabilities. No nomogram was developed in the radiotherapy-alone group because combined
treatment is now the new standard of care. FINDINGS: Independent of the MGMT promoter
methylation status, analysis in all randomised patients (population 1) identified combined treatment with
temozolomide, more extensive tumour resection, younger age, Mini-Mental State Examination (MMSE)
score of 27 or higher, and no corticosteroid treatment at baseline as independent prognostic factors
correlated with improved survival outcome. In patients assigned temozolomide and radiotherapy
(population 2), younger age, better performance status, more extensive tumour resection, and MMSE
score of 27 or higher were associated with better survival. In patients who had tumours resected, who
were assigned temozolomide and radiotherapy, and who had available MGMT promoter methylation
status (population 3), methylated MGMT, better performance status, and MMSE score of 27 or higher
were associated with improved survival. Nomograms were developed and are available at
http://www.eortc.be/tools/gbmcalculator. INTERPRETATION: MGMT promoter methylation status,
age, performance status, extent of resection, and MMSE are suggested as eligibility or stratification
factors for future trials in patients with newly diagnosed glioblastoma. Stratifying by MGMT promoter
methylation status should be mandatory in all glioblastoma trials that use alkylating chemotherapy.
Nomograms can be used to predict an individual patient's prognosis, and they integrate pertinent
molecular information that is consistent with a paradigm shift towards individualised patient
management.
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Abstract 
Purpose: 
To confirm and/or identify new prognostic factors for survival in adult patients with glioblastoma (GBM), derive 
nomograms predicting an individual patient’s prognosis and suggest stratification factors for future trials in newly 
diagnosed GBM patients.    
Patients and Methods 
Data from 573 patients with newly diagnosed GBM randomized to EORTC/NCIC trial 26981-22981/CE.3 were 
included in survival modelling. For 206 patients the methylation status of the MGMT (O6-methylguanine-DNA 
methyltransferase) gene promoter could be assessed. Cox Proportional Hazards models were fit with and without 
the MGMT promoter methylation status. Nomograms were developed to predict an individual patient’s median 
and two year survival probabilities.   
Results 
Independent of the MGMT promoter methylation status, analysis in all randomized patients identified combined 
treatment with temozolomide (TMZ/RT), tumor resection, younger age, a Mini-Mental State Examination (MMSE) 
of 27 or higher and no corticosteroids medication at baseline as independent prognostic factors. In resected 
patients treated by TMZ/RT and available MGMT promoter methylation status assessment, a methylated MGMT, 
a good performance status and a normal MMSE of 27 or higher were associated with an improved survival.  
 
Conclusions 
MGMT promoter methylation status, age, performance status, extent of resection and MMSE are suggested as 
eligibility or stratification factors for future randomized trials in newly diagnosed GBM. Stratifying by MGMT 
promoter methylation status should be mandatory in all GBM trials using alkylating agent chemotherapy. 
Nomograms, electronic versions of which are provided at http://www.eortc.be/tools/gbmcalculator, can be used to 
predict an individual patient’s prognosis. They integrate pertinent molecular patient information in line with a shift 
in paradigm towards individualized patient management. 
Article 
Introduction 
A randomized trial recently published by the European Organisation for Research and Treatment of Cancer 
(EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (EORTC/NCIC trial 26981-
22981/CE.3) demonstrated that the addition of temozolomide to radiotherapy for newly diagnosed glioblastoma 
(GBM) patients significantly improves their survival.(1) Radiotherapy plus concomitant and adjuvant 
temozolomide has rapidly become the new standard of care in Europe and North America. New strategies are 
now being developed building on this treatment as the backbone. Despite this progress, the overall outcome of 
GBM patients remains unsatisfactory, and prognosis is highly variable among various categories of patients.  
Previous studies have identified several clinical factors that help to explain the variability of outcome in GBM 
patients. Age, performance status and the extent of surgical resection are the most consistently reported 
prognostic factors.(2-7) In particular, a recursive partitioning analysis (RPA) carried out by the Radiation Therapy 
Oncology Group (RTOG) has identified four risk classes for GBM (classes III,IV,V and VI) based on the patient’s 
age, Karnofsky performance status, neurological function, mental status and the extent of surgery.(2, 3) In 
addition, the impact of the tumor’s location has been described by several publications. This concerns especially 
the unfavourable influence of midline cranial shift involvement,  of deep seated tumors and the possible 
favourable prognosis of a frontal location. (4-10) 
The unfavourable prognostic impact of an abnormal mental status was first reported by Curran et al. in the original 
paper of the RPA classification, although a formal definition of abnormal mental status was not provided.(2)  In a 
recent study on prognosis in high grade gliomas, the Folstein Mini-Mental State Examination (MMSE) was 
retained together with age and grade in a RPA.(11) Similarly, Brown et al. identified MMSE as a prognostic factor 
in both low-grade and high-grade glioma patients. In another study, they also suggested increased fatigue as an 
independent predictor of poorer survival.(12) (13)  
A decreased expression of the  O6-methylguanine-DNA methyltransferase (MGMT) repair enzyme makes tumors 
sensitive to alkylating agent chemotherapy. Molecular analysis of the tumor tissue of a large subgroup of patients 
demonstrated that the benefit of temozolomide chemotherapy might be limited to patients having a silenced 
MGMT gene by promoter methylation. (14,15)  
The main objective of this study is to confirm or identify new prognostic factors for survival in GBM patients and to 
derive nomograms ie graphical representations of statistical models which predict a particular patient’s prognosis. 
They have been utilized in other cancer sites especially urologic oncology but so far have not been 
applied to neuro-oncology, 
 Patients and Methods 
A total of 573 patients with newly diagnosed GBM (World Health Organization [WHO] astrocytoma grade IV) were 
randomized in EORTC/NCIC trial 22981/26981/CE.3 .(1) Eligibility criteria included age 18 to 70 years, WHO 
performance status less than or equal to 2, and no more than 6 weeks since diagnostic surgery or biopsy. 
Patients received either standard radiotherapy alone or the same radiotherapy plus daily temozolomide followed 
by up to six cycles of adjuvant temozolomide. Patients were stratified by center, age, performance status and 
extent of surgical resection. Other available baseline clinical factors were the sex, tumor location, ongoing 
corticosteroid therapy, MMSE, and the hemoglobin level.   
Age was categorized in three classes of almost equal size (≤50, 51-60 and >60). The cut-off for MMSE i.e. normal 
(27-30) versus impaired  (<27),  was used as previously reported.(11) For hemoglobin, a value ≥ 120 g/L in 
females and 130 g/L. in males was considered normal.  
Assessment of tumor characteristics was based on the local interpretation of preoperative MRI.  Extent of surgical 
resection was determined perioperatively by the neurosurgeon (macroscopically complete versus partial versus 
biopsy only).  
Survival was calculated as the time from randomization until death from cancer or any cause, or censored at the 
date of last follow-up. Compared to previous publications (1, 14,16), this study is based on survival data updated 
in September 2006.  Univariate screening was performed using Kaplan-Meier curves (17), the log-rank test for 
binary variables and the log-rank trend test for ordered categories. In order to identify subgroups of patients with a 
potentially different survival when treated with TMZ/RT compared to those treated by RT alone, treatment by 
factor interaction tests were computed. Factors or treatment by factor interactions with a p-value less than an 
arbitrarily chosen significance level of 10% were candidates for the multivariate analyses. As many factors were 
ordinal, the association between them was estimated by the Spearman rank correlation coefficient (rho).(18)  A 
coefficient less than 0.30 was considered a poor correlation. The Cox proportional hazards model was used with 
forward stepwise model selection using a significance level of 5%. (19) The probability of inclusion of a factor in 
the multivariate model, a criterion for the prognostic importance of the factor, was estimated using the bootstrap 
resampling technique (see supplemental materials). (20)  The variables with a probability of inclusion superior to 
60% based on 1000 bootstrap samples were included in the final model. The methylation status of the MGMT 
promoter was determined retrospectively in a representative subset of 206 (36%) patients where sufficient tumor 
material was available.(14) The subgroup of patients in which the MGMT promoter methylation status was 
assessed was not different from the group of patients without MGMT promoter methylation status assessment 
with respect to known prognostic factors, except for extent of resection. MGMT promoter methylation status could 
not usually be assessed in patients whose tumors were only biopsied due to the lack of a sufficient amount of 
tumor tissue.  
  
Survival modelling was conducted in three patient populations: population 1) the intent-to-treat (ITT) population of 
all randomized patients (n=573), population 2) the subgroup of patients treated by TMZ/RT (n=287), population 3) 
the subgroup of patients who underwent partial or complete resection and were treated by TMZ/RT in the 
presence of an MGMT promoter methylation assessment (n=103).  The reasons for performing the analyses in 
three different populations are the following: 1) it was important to identify main clinical prognostic factors taking 
into account the treatment 2) the strength and importance of some prognostic factors might differ according 
to the treatment administered, in particular in TMZ/RT treated patients 3) the impact of MGMT promoter 
methylation status on the prognosis of TMZ/RT treated patients had to be further evaluated.      
For the three populations, the R “Design” package was used to develop nomograms which predict the median 
survival and the probability of survival at 2 years taking into account the patient’s characteristics. The accuracy of 
predictions was assessed by estimating the models’ calibration and discrimination measured by the Concprdance 
index corrected for optimism (C-index). The C-index is the probability that for two patients chosen at random, the 
patient who had the event first had a higher probability of having the event according to the model. C-index=0.50 
represents agreement by chance; c-index=1.0 represents perfect discrimination (21). Ideally, accuracy of a model 
should be assessed in an independent dataset. If it is no available, the C-index must be corrected for “optimism”. 
The bootstrap technique was used to estimate this correction (see supplemental materials).  
Calibration and discrimination of Cox models based on the RPA classification were also assessed and compared 
to those of our models.  
These prognostic factor analyses are exploratory. Their results are therefore limited by their reduced sample 
sizes, lacks of power and possible selection biases.     
All patients provided written informed consent, and the study was approved by the ethics committees of the 
participating centers.  
The clinical study was supported in part by an unrestricted educational grant by Schering-Plough, Kenilworth, NJ, 
while the study was formally sponsored by EORTC and NCIC. Study design, data collection and analyses, data 
interpretation, writing of the report, or the decision to submit the paper for publication, were the sole responsibility 
of the investigators and collaborators of EORTC and NCIC. For the purpose of the current report, only T.G.,the 
corresponding author, had full access to the raw data in the study and has final responsibility for the decision to 
submit for publication. 
 
Results 
The patient characteristics in population 1 (all randomized patients) are reported in table 1. Overall, MMSE was 
missing in 22 patients (3.8%). Except for the MGMT promoter methylation status, less than 6 patients (1%) had 
data missing for the other factors. The dataset was found representative of the GBM population so that no 
imputation technique was used and patients with missing data were excluded from analysis. Table 2 summarizes 
the univariate survival analyses of each factor by presenting the logrank test p-value. Apart from the hemisphere 
(left/right), all factors passed the 10% statistical significance criterion. Anemic patients showed a better outcome 
compared to patients with normal hemoglobin levels (p=0.04). Nevertheless, the hemoglobin level by treatment 
interaction test was not significant (p=0.11). Both the absence of corticosteroids administration at baseline and the 
extent of surgery were positively correlated with survival. There wasn’t a significant survival difference between 
frontal, temporal, occipital and parietal locations (data not shown). Tumors with central location or mulltifocal (i.e. 
present on more than one lobe) had a worse prognosis than unilobar tumors, they also had a complete resection 
less often (25  vs 201 patients or 24% vs 43%) and such patients more often had an impaired MMSE (42 vs 125 
patients or 44% vs 27%). The last column of table 2 shows p-values of the treatment by factor interaction tests. 
Treatment by performance status was the only interaction test that passed the 10% statistical significance 
criterion (p=0.06). Kaplan-Meier survival estimates for the most important factors are presented in the 
supplemental materials (figures 1 to 6).   
Significant but poor correlations (rho<0.30) between various factors were found. The extent of surgical resection 
was found to be positively correlated with a good performance status (rho=0.15), the absence of corticosteroids 
therapy (rho=0.24), monofocal location (rho=0.17) and a normal mental status (rho=0.16). Younger age was 
positively associated with a good performance status (rho=0.17) and with a normal mental status (rho=0.25). 
Good performance status was positively correlated with the absence of corticosteroids therapy (rho=0.13) and a 
normal mental status (rho=0.25). A negative correlation was found between normal MMSE and mulltifocal or 
central tumor location (rho=0.13). Anemic patients received corticosteroids at randomization less frequently than 
did patients with a normal hemoglobin level (81 vs 323 patients or 58% vs 75%) and they more often underwent a 
complete resection (69 vs 154 patients or 49 % vs 36%). The anemia may thus be due in part to the preceding 
surgery.  
Table 3 presents the results of the multivariate Cox proportional hazards analyses. Factors selected in the final 
model were treatment, age, extent of surgical resection, MMSE and the use of corticosteroids at baseline. The 
probabilities of inclusion (ie. of being selected in the Cox model) were 99.6%,82%,96%,98%,85%, respectively. 
The C-index corrected for optimism was 65.0%.  Accuracy was not improved when age and MMSE were entered 
as continuous factors (C–index corrected for optimism equals 65%). Performance status was not selected and its 
probability of inclusion was 48%. It was however selected in the absence of MMSE in the Cox model.  
For this population, the nomogram is depicted in figure 1 . The patient’s median survival and probability of survival 
at 2 years are obtained by drawing a vertical line from the Total Point axis straight down to the outcome axes (see 
legend).  Alternatively the prognosis can be obtained by summing up the points for each factor in table 4 and 
reading the median survival and probability of survival at 2 years from figure 4. As an example, a patient treated 
by RT alone, disregarding MGMT promoter methylation and performance status, aged 40 years, with a partially 
resected tumor, with a MMSE of 30 and not receiving corticosteroids at baseline has a total prognostic score of 
132 and is predicted to have a 15 months median survival and 24 % chance of surviving 2 years.  
 
Baseline characteristics of population 2 (TMZ/RT treated patients) were similar to those of RT patients (table 1).  
Table 2 summarizes the univariate analyses of each factor by presenting the medians with 95% confidence 
intervals, p-values and hazard ratios with 95% confidence intervals in each of the two treatment groups. For 
instance, patients with a MMSE less than 27 treated by TMZ/RT had a risk of death of 1.87 times that of patients 
with MMSE in the range 27 to 30. 
Apart from the hemisphere (left/right) and sex, all factors passed the 10% statistical significance criterion. Here 
also, anemic patients showed a better outcome compared to patients with normal hemoglobin levels (p=0.023).  
In multivariate analyses (table 3), factors selected and included in the final model were age (p=0.008, probability 
of inclusion 80%), performance status (p=0.006, 78%), extent of surgery (p<0.001, 75%) and MMSE (p<0.001, 
79%).  In this subset, corticosteroids were not selected (p>0.05, 33%). Sex was selected but had a percentage of 
inclusion in bootstrap simulations less than 60% (p=0.03, 55%) and therefore was excluded from the final model. 
The C-index corrected for optimism was 63.0%.  
Since the performance status by treatment interaction test was significant and this factor was selected in the 
TMZ/RT population but not in the population of all randomized patients (population 1), a Cox model was also fit in 
patients treated by RT alone. In this subset, extent of surgery (p=0.007, 80%), MMSE (p<0.0001, 89%) and 
corticosteroids (p=0.005, 81%) were selected but not age (p>0.05, 29%) or performance status (p>0.05, 8%). 
Anemic patients did not show a better outcome compared to patients with normal hemoglobin levels (p=0.71).  
The resulting nomogram is shown in figure 2. Prognosis can also be obtained from table 4 and figure 5.  
As an example, the same patient presented in the all randomized patients population with a performance status 0 
has a total prognostic score of 50 and has a predicted 20 months median survival and 42.5% probability of 
survival at 2 years.   
 
Patients in population 3 (TMZ/RT treated patients, resected tumor and MGMT promoter methylation status 
assessed) were slightly younger (median: 53 [19-70] vs 56 [18-70] yrs), and more often had a frontal tumor 
(40.8% vs 27.0%). Patients with biopsy only were less likely to have MGMT promoter methylation assessed and 
were not included. With such a high percentage of missing data no substantial benefit was expected from 
imputation techniques and therefore analyses were performed in the complete dataset.     
The MGMT promoter methylation status was not found to be correlated with age or with any of the other 
prognostic factors tested.   
Due to the limited sample size and power of the analyses, factors selected in the univariate analyses in the 
TMZ/RT population were also considered for the multivariate analysis in this population. 
The final multivariate Cox model in table 3 included the MGMT promoter methylation status (p<0.0001, 92%), 
performance status (p=0.003, 82%) and MMSE (p=0.008, 81%). The C-index corrected for optimism was 65,5%.  
The resulting nomogram is shown in figure 3. Prognosis can also be obtained from table 4 and figure 6.  As an 
example, the patient reported in the previous populations is predicted to have 48.0 compared to 16.9 months 
median survival and a 66% compared to 32.5% probability of survival at 2 years, in MGMT promoter methylated 
versus unmethylated tumors, respectively. 
The nomogram in the population of all randomized patients (population 1) was well calibrated but could not make 
an accurate prediction for patients with a probability of survival at 2 years superior to 40%.  The nomograms in the 
two other populations could predict patients with a survival probability at 2 years greater than 40% but were less 
well calibrated and predictions were less accurate (more detail on nomograms’ calibration is available at    
http://www.eortc.be/tools/gbmcalculator/calibration.htm).. We show in supplemental materials that predictions of 
our nomograms are more accurate than those of models based on the RPA classification. C-index of RPA based 
models is 58.4%, 58.9% and 55.5% in populations 1, 2 and 3 respectively (see supplementary table 1). Accuracy 
was particulary low for RPA classes III and V.  
 
 
 
Discussion 
A proper understanding of prognostic factors is important for the counseling of individual patients, to select 
patients for specific treatments and for the design and interpretation of clinical trials. EORTC/NCIC trial 26981-
22981/CE.3 showed that treatment with concurrent and adjuvant temozolomide in addition to radiotherapy 
improved the overall outcome as compared to radiotherapy alone.(1) This companion prognostic factor analysis 
has identified treatment with RT and concomitant and adjuvant treatment with temozolomide, age, extent of 
surgical resection, MGMT promoter methylation status, WHO performance status, neurological function 
expressed by the MMSE as well as the need for corticosteroids administration after surgery or biopsy as the most 
relevant independent prognostic factors for the outcome of GBM patients. Although the prognostic significance of 
some of these factors has been identified before, the significant negative prognostic impact of the presence of 
corticosteroid treatment at baseline  in patients treated by RT alone but not when treated by TMZ/RT, and iWHO 
performance status and age being significantly correlated with survival in patients treated by TMZ/RT but not 
when treated by RT alone are novel findings which deserve further investigation.   
Corticosteroid use was identified as a poor prognostic factor in an old, small study with a heterogeneous patient 
population, but has not been assessed in most more recent trials.(22)  Its use may identify patients with more 
severe clinical signs and symptoms prior to surgery, or with larger tumors or tumors that were amenable to a 
biopsy only. Finally, the efficacy of this therapy seems to be enhanced in patients with a good performance status. 
In both cases, confirmations in future trials are needed.  
Our trial confirmed the presence of a strong relation between outcome and extent of tumor resection; however the 
interpretation is limited by the fact that the extent of resection was based on perioperative assessment by the 
neurosurgeon without a mandatory postoperative radiological confirmation. This limits the reliability of the 
distinction between partially and completely resected patients. The study was not randomized for this issue, and 
we could not identify the relevance of the extent of resection in the subset of patients with known MGMT promoter 
status. Therefore the relative contribution from attempting maximal resection cannot be assessed. It therefore 
remains unclear from these data if a more extensive resection improves the outcome. However, in view of the 
better outcome of resected patients in many studies, all GBM patients should undergo as extensive a resection as 
is safely possible.(1)  
Our trial demonstrated that combined and adjuvant temozolomide treatment improves outcome. It also suggests, 
although not reaching statistical significance,,that the subset of patients with a methylated MGMT promoter 
particularly benefits from the addition of temozolomide.  Even patients not treated with concomitant and adjuvant 
chemotherapy presented with a better outcome in the presence of a methylated MGMT promoter, probably due to 
a greater efficacy of salvage chemotherapy with alkylating agents administered at the time of recurrence. (14)  
Earlier studies in which all patients received adjuvant BCNU in addition to radiotherapy also found 
alkyltransferase expression of prognostic significance.(23, 24) .We discussed elsewhere the influence of 
stratifying by this molecular marker in the development of new therapeutic strategies for GBM patients (15).  
The present analysis did not show any correlation between age and the MGMT promoter methylation status, 
which implies that the poor prognosis of elderly patients cannot be explained by a lower frequency of MGMT 
promoter methylation. In contrast, in the presence of MGMT promoter methylation information, age was no longer 
retained in the model and the nomogram.  This suggests that older patients with methylated MGMT promoter 
might benefit from the new combination therapy despite their age. It cannot be excluded that this might be due to 
the lack of power in this subgroup analysis. Additional data will be necessary to assess the effect of TMZ/RT in 
this subgroup. 
In a RPA, the RTOG identified 6 prognostic classes of anaplastic gliomas based on clinical factors, in which 
classes III through VI are applicable to GBMs. However, this system developed and validated in the early 1990’s 
is based on data collected from 1974 to 1994. During the 3 decades since 1974 not only have diagnostic tools, 
radiotherapy planning and treatment techniques dramatically changed but also the histopathological classification 
systems have been revised, and molecular factors relevant for outcome have been identified. Within the current 
clinical context, we have previously shown that RPA prognostic classes still separate prognostic groups after 
combined chemo-radiotherapy with temozolomide in newly diagnosed GBM. (16,25)  
 
The present analysis adds a new dimension to the previous studies, in that it approaches prognosis from the 
individual patient’s perspective: the nomogram offers a more tailored approach for individual patients taking their 
individual prognostic factors into account. Investigators might want to use their prediction in groups of patients 
from small phase II trials investigating innovative adjuvant treatment strategies in order to evaluate if improved 
outcome is not a consequence of patient selection. As formal comparisons are not possible in phase II trials, this 
use of nomograms should be limited to guide further research only.  We claim that nomograms predictions are 
more accurate than those based on the RPA classification and therefore better adapted to investigate tailored 
therapeutic options for individual patients.  
This study is exploratory and a limitation of these nomograms is of course that there is no validation yet possible 
in a large independent set of patients.(3, 26) At present no other large datasets are available on radiotherapy with 
concurrent and adjuvant temozolomide chemotherapy treated patients including the MMSE score and the MGMT 
promoter methylation status. Some analyses have been performed in sub-groups of patients, in particular in those 
with sufficient biological materials for MGMT promoter methylation assessment. Validity and generalizability of 
these nomograms need to be evaluated in prospectively acquired data.    
Electronic versions of the nomograms are available at http://www.eortc.be/tools/gbmcalculator.  
In future trials of newly diagnosed GBM, the MGMT promoter methylation status, age, performance status, extent 
of resection and MMSE should be considered as eligibility criteria and/or stratification factors. Stratifying by 
MGMT promoter methylation status should be mandatory in both adjuvant and recurrent GBM trials that include 
the administration of alkylating agents. When the MGMT promoter methylation status cannot be assessed before 
randomization, it should be determined after inclusion of the patients and used as a correction factor in the 
survival analyses.  
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Figure 1. Nomograms for predicting median survival and probability of survival at 2 years in all 
randomized patients (population 1),  
Figure 2. Nomograms for predicting median survival and probability of survival at 2 years in patients 
treated by TMZ/RT (population 2) 
Figure 3. Nomograms for predicting median survival and probability of survival at 2 years in patients 
treated by TMZ/RT who underwent complete or partial resection in presence of MGMT promoter 
methylation status assessment (population 3). 
Legend: First, choose the patient’s treatment on the Treatment axis. Draw a line straight upwards to the points axis and record 
by how many points survival outcome is affected when the patient receives the treatment. This process must be repeated for the 
other axes. For each predictor, points must be summed and the sum must be located on the Total Point axis. A line straight 
down must be drawn to get an estimate of the patient’s median survival and 24 months probability of survival at 2 years. 
 
Figure 4. Prognostic plots for the nomograms in all randomized patients (population 1).  
Figure 5. Prognostic plots for the nomograms in patients treated by TMZ/RT (population 2). 
Figure 6. Prognostic plots for the nomograms in patients treated by TMZ/RT who underwent complete or 
partial resection in presence of MGMT promoter methylation status assessment (population 3). 
Legend: Median survival in months (dashed line, left y-axis) and probability of survival at 2 years (solid line, right y-axis) are 
plotted as a function of the total prognostic score.  
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Supplementary methods 
Development of nomograms 
The main goals of staging systems like nomograms are to provide as accurate as possible predictions 
for specified endpoints. To be useful in the clinic, they must be sufficiently practical and must include 
easily available and measured parameters (1,2).  We claim that our nomograms fulfill these conditions. 
In this study, three multivariate Cox’s proportional hazards models for overall survival were fit in three 
different populations with a set of prognostic factors initially screened by univariate analyses (3). 
Coefficients of the three Cox regression models were utilized to generate nomograms that predict for 
individual patient’s median survival for those patients with similar characteristics and probability of 
survival at 2 years.  For each nomogram and patient, the Cox regression linear predictor function (LPj) 
was obtained by summing up the products between the characteristic i of patient j (Xij) and 
corresponding Cox coefficient (βi):  
∑β=
i
ijij X*LP  
Baseline value LPj  equals 0 and corresponds to the best prognosis patients.   
For each factor, prognostic scores presented in table 4 of the manuscript are given by the following 
formula: 
100*
X*
 i sticcharacteri of each valuefor  score Prognostic iji
Β
β
=  
Where B is the Cox coefficient corresponding to the factor with the maximum product iji X*β  
The formula for median survival taking into account the patient’s characteristics: 
jLP
e*)5.0ln(uwhere}uH:t{imumminSurvivalMedian jj0j
−
−=≥=  
It is the smallest time (t) corresponding to a value of the baseline cumulative hazard (H0) superior or 
equal to uj. When LPj=0, it provides the median survival of the best prognosis patients. 
The probability of survival at 2 years is given by the following formula: 
jLPe
0j Syears2atsurvivalofobabilityPr =  
 
Where, S0 is the probability of survival at 2 years for patients with the best prognosis.  
 
What is the bootstrap technique and what does it do ? 
 
The bootstrap is a simulation technique first described by Bradley Efron (4). The idea is that the original 
dataset is a random sample of patients representative of a general population.  Bootstrapping means 
generating a large number of datasets each of which with the same sample size as the original one by 
resampling with replacement (ie. an already selected patient may be selected again). From these 
replicated datasets, uncertainties around estimates or inferences can be measured.  
 
Measuring and comparing nomograms predictions’ accuracy 
 
Accuracy is defined as the degree of conformity with a standard or a true value or the degree of 
correctness attained in a measure. Accuracy is useful to quantify the utility of a predictor or model, 
diagnose for model overfitting or lack of fit. Accuracy of competing models can be compared. Accuracy 
can be assessed by two parameters: discrimination and calibration (5). 
 
Discrimination measures a predictor’s ability to separate patients with different prognosis. It is quantified 
by the Concordance Index (Harrel’s C-index) which is the proportion of all usable patient pairs in which 
the predictions and observations are in agreement; i.e. the probability that for two patients chosen at 
random, the patient who had the event first had a higher probability of having the event according to the 
model. It ranges from 0.5 (agreement by chance) to 1.0 (perfect discrimination ability). 
 
Calibration refers to the ability to provide unbiased survival predictions in groups of similar patients. This 
ability is assessed by visual examination of calibration plots.  In our calibration plots (see supplementary 
figures 7-12), horizontal axis is prediction (provided by our nomograms or Cox models based on the 
RPA classification) for the probability of survival at 2 years. Vertical axis is the observed proportion of 
patients surviving 2 years. Dashed line represents a perfectly calibrated nomogram. Solid line is current 
prediction model performance with 95% confidence intervals. { represents subgroups of patients with 
different predicted probability of surviving 2 years. ¯ represents the bootstrap-corrected estimate of 
nomogram performance (see below for more details on the use of the bootstrap technique).  
A prediction model was considered “well calibrated” if the difference between predictions and 
observations in all groups of similar patients was close to 0 (perfect calibration).  Any large deviation (eg. 
>5%) indicated lack of calibration.   
 
Measuring the accuracy of a multivariate model in the training dataset provides generally too optimistic 
estimates. Ideally, accuracy should be assessed in an independent dataset from the same population. In 
this study, no large validation dataset including both the MGMT promoter methylation status and MMSE 
was available.  As a substitute, the bootstrap technique was used to best estimate the likely external 
validation accuracy of our models.  Corrections for optimism were calculated for the calibration plots and 
the C-index. The bootstrap technique was also used for each factor to estimate its probability of being 
selected into a Cox model and to assess its importance for the prediction. Cox models were fit on 1000 
bootstrap resampling and the probability of inclusion of each factor was estimated by the proportion of 
samples with the factor included in the set of prognosticators selected by the stepwise method.   
 
The R “Design” package used to assess these parameters is a program developed by Harell FE in the R 
language. It can be downloaded from the URL: 
http://cran.cnr.berkeley.edu/src/contrib/Descriptions/Design.html 
Accuracy comparison of predictions based on our nomograms and on those of Cox models 
based on the RPA classification: 
 
Mirimanoff RO et al (6) showed in a previous report based on the same dataset that RPA classification 
retained its prognostic significance in Glioblastoma patients treated by irradiation with or without 
Temozolomide. RPA classes had to be adapted because performance status and mental status scales 
were different from those used in the original RTOG study. We used the same definitions in this study. 
Accuracy of predictions based on our nomograms and on those of Cox models with the RPA class 
entered as an ordered factor (called RPA models) was compared with the calibration and discrimination 
parameters.   
Supplementary results 
 
Supplementary Figure 1. Kaplan Meier estimates of Overall Survival according to age (all randomized 
patients: population 1, n=573) . 
Supplementary Figure 2. Kaplan Meier estimates of Overall Survival according to the extent  of 
surgery (all randomized patients: population 1, n=573) . 
Supplementary Figure 3. Kaplan Meier estimates of Overall Survival according to the Mini-Mental 
State Examination (all randomized patients: population 1, n=573) . 
Supplementary Figure 4. Kaplan Meier estimates of Overall Survival according to the administration 
of Corticosteroids at baseline (all randomized patients: population 1, n=573) . 
Supplementary Figure 5. Kaplan Meier estimates of Overall Survival according to the WHO 
performance status (all randomized patients: population 1, n=573) . 
Supplementary Figure 6. Kaplan Meier estimates of Overall Survival according to the MGMT 
promoter methylation status in the population of resected patient (all randomized patients with tumor 
resection and MGMT promoter methylation status assessed, n=199) .  
 
 
 
Comparison of accuracy of predictions based on our nomograms and on those of Cox models 
based on the RPA classification: 
 
Discrimination 
The C-indexes corrected for optimism were lower in all three RPA models compared to nomograms 
(58.4% vs 65.0%, supplementary table 1).  The discrimination of the RPA model in the population of 
TMZ/RT treated patients, resected tumor and MGMT promoter methylation status assessed was 
particularly low (55.5% versus 65.5%).  
Supplementary table 1. Concordance Indexes corrected for optimism of the nomograms and RPA 
classification in the three study populations.  
Calibration 
More detail on nomograms’ calibration is available at    
http://www.eortc.be/tools/gbmcalculator/calibration.htm.   
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Table 1. Patient demographics and baseline characteristics 
 Population 1 ‡ 
(n=573) 
RT alone  
patients 
(n=286) 
Population 2 ‡ 
(n=287) 
Population 3 ‡ 
(n=103) 
 
Not in 
population 3 ‡ 
(n=470) 
Factor No. of Patients 
(%) 
No. of Patients 
(%) 
No. of Patients 
(%) 
No. of Patients 
(%) 
No. of Patients 
(%) 
Extent of surgery 
Biopsy  
Partial 
Complete 
 
93 (16.2) 
254 (44.3) 
226 (39.4) 
 
45 (15.7) 
128 (44.8) 
113 (39.5) 
 
48 (16.7) 
126 (43.9) 
113 (39.4) 
 
0 (0.0) 
56 (54.4) 
47 (45.6) 
 
93 (19.8) 
198 (42.1) 
179 (38.1) 
 
Age  
≤50 years 
51-60 years  
>60 years 
 
 
183 (31.9) 
220 (38.4) 
170 (29.7) 
 
 
88 (30.8) 
111 (38.8) 
87 (30.4) 
 
 
95 (33.1) 
109 (38.0) 
83 (28.9) 
 
 
44 (42.7) 
40 (38.8) 
19 (18.4) 
 
 
139 (29.6) 
180 (38.3) 
151 (32.1) 
 
WHO performance 
status 
0 
1 
2 
 
 
 
 
223(38.9) 
277 (48.3) 
73 (12.7) 
 
 
 
 
110 (38.5) 
141 (49.3) 
35 (12.2) 
 
 
 
 
113 (39.4) 
136 (47.4) 
38 (13.2) 
 
 
 
 
42 (40.8) 
49 (47.6) 
12 (11.7) 
 
 
 
 
181 (38.5) 
228 (48.5) 
61 (13.0) 
 
Sex 
Male 
Female 
Not recorded 
 
 
360 (62.8) 
212 (37.0) 
1 (0.2) 
 
 
175(61.2) 
110 (38.5) 
1 (0.3) 
 
 
185 (64.5) 
102 (35.5) 
0 (0.0) 
 
 
65 (63.1) 
38 (36.9) 
0 (0.0) 
 
 
295 (62.8) 
174 (37.0) 
1 (0.2) 
 
Corticosteroids at  
randomization  
No 
Yes 
Missing 
 
 
 
164 (28.6) 
408 (71.2) 
1 (0.2) 
 
 
 
70 (24.5) 
215 (75.2) 
1 (0.3) 
 
 
 
94 (32.8) 
193 (67.2) 
0 (0.0) 
 
 
 
31 (30.1) 
72 (69.9) 
0 (0.0) 
 
 
 
133 (28.3) 
336 (71.5) 
1 (0.2) 
 
MMSE 
27-30 
<27 
Missing 
 
 
167 (29.1) 
384 (67.0) 
22 (3.8) 
 
 
86 (30.1) 
188 (65.7) 
12 (4.2) 
 
 
81 (28.2) 
196 (68.3) 
10 (3.5) 
 
 
24 (23.3) 
75 (72.8) 
   4 ( 3.9) 
 
 
143 (30.4) 
309 (65.7) 
  18 ( 3.8) 
 
Lobe 
Frontal 
Temporal 
Parietal 
Occipital 
Central 
Multifocal 
Other 
Missing 
 
 
169 (29.5) 
160 (27.9) 
101 (17.6) 
37 (6.5) 
20 (3.5) 
79 (13.8) 
4 (0.7) 
3 (0.5) 
 
 
82 (28.7) 
79 (27.6) 
54 (18.9) 
17 (5.9) 
7 (2.4) 
40 (14.0) 
4 (1.4) 
3 (1.0) 
 
 
87 (30.3) 
81 (28.2) 
47 (16.4) 
20 (7.0) 
13 (4.5) 
39 (13.6) 
0 (0.0) 
0 (0.0) 
 
 
  42 (40.8)  
  30 (29.1)  
  10 ( 9.7)  
   8 ( 7.8)  
   1 ( 1.0)  
  12 (11.7)  
   0 ( 0.0)  
   0 ( 0.0)  
 
 
127 (27.0) 
130 (27.7) 
91 (19.4) 
29 ( 6.2) 
19 ( 4.0) 
67 (14.3) 
4 ( 0.9) 
3 ( 0.5) 
Hemisphere 
Right 
Left 
Both 
Missing 
 
297 (51.8) 
269 (46.9) 
5 (0.9) 
2 (0.3) 
 
146 (51.0) 
135 (47.2) 
3 (1.0) 
2 (0.7) 
 
151 (52.6) 
134 (46.7) 
2 (0.7) 
0 (0.0) 
 
57 (55.3) 
46 (44.7) 
0 ( 0.0) 
0 ( 0.0) 
 
240 (51.1) 
223 (47.4) 
5 ( 1.1) 
2 ( 0.4) 
 
Hemoglobin level 
Anemia 
Normal 
Missing 
 
 
140 (24.4) 
429 (74.9) 
4 (0.7) 
 
 
72 (25.2) 
214 (74.8) 
0 (0.0) 
 
 
68 (23.7) 
215 (74.9) 
4 (1.4) 
 
 
24 (23.3) 
77 (74.8) 
2 (1.9) 
 
 
116 (24.7) 
352 (74.9) 
2 ( 0.4) 
 
MGMT promoter 
methylation 
status 
Methylated 
Unmethylated 
Unknown 
 
 
 
 
92 (16.1) 
114 (19.9) 
367 (64.0) 
 
 
 
 
46 (16.1) 
54 (18.9) 
186 (65.0) 
 
 
 
 
46 (16.0) 
60 (20.9) 
181 (63.1) 
 
 
 
 
45 (43.7) 
58 (56.3) 
0 ( 0.0) 
 
 
 
 
47 (10.0) 
56 (11.9) 
367 (78.1) 
Legend: ‡ population 1: all randomized patients (ITT), population 2 :  all patients treated by TMZ/RT, 
population 3: patients who underwent partial or complete resection treated by TMZ/RT with MGMT 
assessment available, not in population 3: RT alone patients or with biopsy or without MGMT promoter 
methylation status assessed 
 
 
Table 2. Univariate analyses of potential survival prognostic factors 
 RT alone patients 
(n=286) 
Population 2 ‡ 
(n=287) 
Population 1 ‡ 
(n=573) 
Treatment 
Interaction test 
 
 Median 
survival/95% 
CI  (months) 
HR-
95%CI 
p-value    Median
survival 
/95% CI  
(months) 
HR-
95%CI 
p-value HR-95%CI p-value p-value 
Treatment 
Temozolomide and 
radiotherapy 
Radiotherapy 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
 
1 
 
1.57 [1.32-1.87] 
 
<0.0001 
 
N/A 
Extent of surgery µ 
Complete resection 
Partial resection 
Biopsy 
 
14.2 (13.0-
16.2) 
11.7 (9.7-
13.1) 
7.9 (6.4-
10.6) 
 
1.45(1.22-
1.73) 
 
<0.0001 
 
18.8 (16.4-
22.9) 
13.5 (11.9-
16.4) 
9.4 (7.5-
13.6) 
 
1.46(1.22-
1.74) 
 
<0.0001 
 
1.44[1.27-1.63] 
 
<0.0001 
 
0.41 
 
Age  µ 
≤50 years  
51-60 years  
>60 years 
 
 
13.6 (11.6-
15.6) 
12.0 (10.0-
14.2) 
11.8 (10.5-
12.8) 
 
 
1.16(1.00-
1.36) 
 
 
0.054 
 
 
 
 
17.4 (15.3-
21.5) 
14.6 (13.6-
17.9) 
11.3 (9.4-
15.1) 
 
 
1.34 
(1.14-
1.57) 
 
 
0.0004 
 
 
 
 
1.26 [1.13-1.41] 
 
 
<0.0001 
 
 
0.17 
 
WHO performance status 
µ 
0 
1 
2 
 
 
 
13.3 (11.8-
15.7) 
11.9 (10.0-
13.2) 
10.5 (8.5-
13.0) 
 
 
 
1.19 
(1.00-
1.42) 
 
 
 
0.050 
 
 
 
17.4 (15.7-
21.2) 
14.1 (12.5-
17.0) 
9.9 (6.9-
12.1) 
 
 
 
1.47 
(1.21-
1.79) 
 
 
 
0.0001 
 
 
 
1.33 [1.17-1.51] 
 
 
 
 
 
<0.0001 
 
 
 
0.06 
 
Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female 
Male 
12.6 (11.9-
16.1) 
11.4 (10.5-
12.9) 
1.24(0.97-
1.59) 
0.08 16.3 (13.4-
20.4) 
14.4 (12.4-
16.4) 
1.16(0.89-
1.51) 
0.26 
 
 
1.17 [0.98-1.40] 0.09 0.87 
 
Corticosteroids at 
randomization  
No 
Yes 
 
 
 
16.3 (14.4-
17.3) 
11.0 (9.7-
12.1) 
 
 
 
1.70 
(1.29-
2.25) 
 
 
 
0.0002 
 
 
 
19.7 (16.4-
24.9) 
13.6 (11.9-
14.9) 
 
 
 
1.47(1.12-
1.94) 
 
 
 
0.005 
 
 
 
1.60 [1.32-1.95] 
 
 
 
 
<0.0001 
 
 
 
0.92 
 
MMSE 
27-30 
<27 
 
 
13.3 (12.2-
14.8) 
9.3 (7.9-
11.7) 
 
 
1.78 
(1.37-
2.31) 
 
 
<0.0001 
 
 
 
 
17.1 (15.3-
19.1) 
10.3 (8.6-
12.9) 
 
 
1.87 
(1.43-
2.46) 
 
 
<0.0001 
 
 
 
 
1.81 [1.50-2.19] 
 
 
<0.0001 
 
 
0.41 
 
Lobe 
Unilobal 
Central & multilobal 
 
 
12.5 (12.0-
14.1) 
9.5 (7.5-
11.7) 
 
 
1.40(1.02-
1.91) 
 
 
 
0.03 
 
 
16.3 (14.4-
18.3) 
11.3 (9.2-
14.0) 
 
 
1.76 
(1.28-
2.42) 
 
 
0.0004 
 
 
 
1.58 [1.26-1.96] 
 
 
<0.0001 
 
 
0.20 
Hemisphere 
Right 
Left 
 
 
13.0 (11.9-
14.4) 
11.4 (10.0-
12.3) 
 
 
1.07 
(0.84-
1.36) 
 
 
 
0.28 
 
15.7 (13.9-
18.1) 
14.4 (12.4-
17.0) 
 
 
.00 (0.80-
1.30) 
 
0.92 
1  
 
1.05 [0.88-1.24] 
 
0.62 
 
0.89 
 
Hemoglobin level 
Anemia 
Normal 
 
 
11.4 (10.0-
13.3) 
12.2 (11.4-
13.5) 
 
 
1.05 
(0.80-
1.39) 
 
 
0.71 
 
 
18.6 (15.7-
25.9) 
13.5 (12.2-
15.5) 
 
 
1.41 
(1.05-
1.89) 
 
 
0.023 
 
 
 
 
1.24 [1.01-1.52] 
 
 
0.04 
 
 
0.11 
 
MGMT promoter 
methylation 
Methylated 
 
 
15.3 (13.0-
20.9) 
 
 
2.40 
(1.53-
 
 
0.0001 
 
 
21.7 (18.6-
N) 
 
 
2.24 
(1.43-
 
 
0.0003 
 
 
2.10 [1.54-2.85] 
 
 
<0.0001 
 
 
 
0.31 
Unmethylated    11.8 (10.0-
14.4) 
3.78) 12.4 (11.6-
14.4) 
3.51) 
µ : For ordered categorical factors, the first value is the reference. HR = 1.x% means that death rate is increased by x% on average between patients 
belonging to adjacent groups. E.g. For age in population 1, HR=1.16 indicates a death rate increase of 16% between age <=50 and 51-60 and 
the same increase between class 51-60 and >60. 
 
Table 3. Cox Proportional Hazards analyses of survival prognostic factors  
 Population 1 * 
(n=573, # used=547, # deaths=498) 
RT alone patients 
(n=286, #used=274, # deaths=263) 
Population 2 * 
(n=287, # used=273,# deaths=235) 
Population 3 * 
(n=103,# used=97, # deaths=77) 
 Hazard Ratio 
(95% CI) 
P(% inclusion) Hazard Ratio 
(95% CI) 
P(% inclusion) Hazard Ratio 
(95% CI) 
P(% inclusion) Hazard Ratio 
(95% CI) 
P(% inclusion) 
Treatment assignment 
Temozolomide and Radiotherapy  
Radiotherapy  
 
1 
1.60 (1.34-1.91) 
 
<0.0001 (99.6) 
 
NI 
 
NI 
 
NI 
 
NI 
 
NI 
 
NI 
MGMT promoter  
Methylated 
Unmethylated 
NI       NI NI NI NI NI
2.75 (1.68-4.49) 
 
<0.0001(92) 
Age µ 
≤50 years  
51-60 years  
>60 years 
 
1.19(1.06-1.34) 
0.003 (82)  
1.12 [0.95-1.32] 
 
NS (29) 
 
1.26 (1.06-1.48) 
0.008(80)  
1.32 [0.95-1.84] 
NS(37) 
Performance status µ 
0 
1 
2 
 
1.12 [0.98-1.28] 
NS(48)  
0.98 [0.82-1.19] 
 
NS (8) 
 
1.32 (1.08-1.60) 
0.006(78)  
1.76 (1.21-2.55) 
0.003(82) 
Interaction term between 
performance status & Treatment  
 
0.99 [0.82-1.19] 
NS(40)       NI NI NI NI NI NI
Extent of surgery µ 
Complete resection 
Partial resection 
Biopsy 
 
1.33 (1.17-1.52) 
 
<0.0001(96) 1.29 (1.07-1.55) 0.007 (80)  
1.37 (1.14-1.63) 
<0.001(75)  
1.03 [0.64-1.64] 
 
NS(7)† 
Tumor location  
Unilobal 
Central & multilobal 
 
1.17 [0.92-1.50] 
NS(30)  
0.94 [0.66-1.33] 
NS (13)  
1.40 [0.99-1.97] 
NS(52)  
1.62 [0.80-3.29] 
NS(41) 
MMSE  
27-30 
<27 
 
1.63 (1.34-1.98) 
<0.0001(98)    1.71(1.31-2.24) <0.0001 (89)
1.66 (1.25-2.19) 
<0.001 (79)  
1.98 (1.20-3.28) 
0.008(81) 
Corticosteroids  
No 
Yes 
1.36 (1.11-1.67) 0.003(85) 1.52 (1.13-2.03) 0.005 (81)  
1.19 [0.89-1.59] 
NS(33)  
1.17 [0.70-1.97] 
NS(12) 
Sex  
Female 
Male  
 
1.16 [0.97-1.40] 
 
NS(51) 
 
1.13 [0.88-1.46] 
NS (22)  
1.30 [0.99-1.70] 
0.03‡(55)  
1.10 [0.69-1.77] 
NS(10) 
Hemoglobin level 
Anemia 
Normal 
 
1.06 [0.86-1.31] 
NS(9)    
0.96 [0.72-1.28] 
NS (9)  
1.33 [0.98-1.81] 
NS(36)
1.44 [0.85-2.46] 
NS(21) 
C-Index corrected for otimism 65%    NI 63% 65.5%
µ : For ordered categorical factors, the first value is the reference. HR = 1.x% means that death rate is increased by x% on average between patients 
belonging to adjacent groups. E.g. For age in population 1, HR=1.19 indicates a death rate increase of 19% between age <=50 and 51-60 and 
the same increase between class 51-60 and >60. 
 
Table 4: Prognostic scores of each factor in the three nomograms   
 
Factor Population 1 ‡ 
(n=573) 
Population 2 ‡ 
 (n=287) 
 
Population 3 ‡  
(n=103) 
Treatment 
 TMZ/RT 
 RT alone 
 
0 
82 
 
N/A 
 
N/A 
MGMT promoter 
 Methylated 
 Unmethylated 
 
NI 
 
 
NI 
 
0 
90 
Age (years) 
 ≤50  
 51-60 
 >60 
 
0 
31 
61 
 
0 
35 
71 
 
NI 
Extent of surgery 
 Total 
 Partial  
 Biopsy 
 
0 
50 
100 
 
0 
50 
100 
 
NI 
WHO performance status 
 0 
 1 
 2 
 
NI 
 
0 
41 
82 
 
0 
50 
100 
MMSE 
 27-30 
 <27 
 
0 
85 
 
0 
78 
 
0 
61 
Corticosteroids 
 No 
 Yes 
 
0 
54 
 
NI 
 
 
NI 
Total Points 0-382 0-331 0-251 
Legend: N/A : not applicable. NI Not included: factor was not included in the final model. Points must be 
summed-up to obtain a total prognostic score. Good prognoses have a low total prognostic score. ‡ 
population 1: all randomized patients (ITT), population 2 :  all patients treated by TMZ/RT, population 3: 
patients who underwent partial or complete resection treated by TMZ/RT with MGMT assessment 
available. 
 






Supplementary table 1. Concordance Indexes corrected for optimism of the nomograms and RPA 
classification in the three study populations.  
Concordance-index 
corrected for optimism 
Population 1 ‡ Population 2 ‡ Population 3 ‡ 
RPA classification 58.4% 58.9% 55.5% 
Nomograms 65.0% 63.0% 65.5% 
Legend: ‡ Population 1: all randomized patients (ITT), population 2 :  all patients treated by TMZ/RT, 
population 3: patients who underwent partial or complete resection treated by TMZ/RT with MGMT 
assessment available. 
 
 
